- Home
- AIMD vs LIXT Comparison
AIMD vs LIXT Comparison
Compare AIMD & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIMD
- LIXT
- Stock Information
- Founded
- AIMD 1984
- LIXT 2005
- Country
- AIMD United States
- LIXT United States
- Employees
- AIMD N/A
- LIXT N/A
- Industry
- AIMD Biotechnology: Pharmaceutical Preparations
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- AIMD Health Care
- LIXT Health Care
- Exchange
- AIMD Nasdaq
- LIXT Nasdaq
- Market Cap
- AIMD 11.9M
- LIXT 12.4M
- IPO Year
- AIMD N/A
- LIXT N/A
- Fundamental
- Price
- AIMD $3.63
- LIXT $4.47
- Analyst Decision
- AIMD
- LIXT
- Analyst Count
- AIMD 0
- LIXT 0
- Target Price
- AIMD N/A
- LIXT N/A
- AVG Volume (30 Days)
- AIMD 235.1K
- LIXT 121.5K
- Earning Date
- AIMD 08-13-2025
- LIXT 08-07-2025
- Dividend Yield
- AIMD N/A
- LIXT N/A
- EPS Growth
- AIMD N/A
- LIXT N/A
- EPS
- AIMD N/A
- LIXT N/A
- Revenue
- AIMD $110,870.00
- LIXT N/A
- Revenue This Year
- AIMD N/A
- LIXT N/A
- Revenue Next Year
- AIMD N/A
- LIXT N/A
- P/E Ratio
- AIMD N/A
- LIXT N/A
- Revenue Growth
- AIMD 70.25
- LIXT N/A
- 52 Week Low
- AIMD $2.00
- LIXT $0.64
- 52 Week High
- AIMD $5.00
- LIXT $5.14
- Technical
- Relative Strength Index (RSI)
- AIMD 54.86
- LIXT 58.29
- Support Level
- AIMD $3.56
- LIXT $3.20
- Resistance Level
- AIMD $4.19
- LIXT $4.60
- Average True Range (ATR)
- AIMD 0.27
- LIXT 0.51
- MACD
- AIMD -0.01
- LIXT 0.06
- Stochastic Oscillator
- AIMD 38.46
- LIXT 78.53
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.